Evidence map›Paper›PMID 28959525›Full record

ArticleToxicology reports2016

Diosmetin protects against retinal injury via reduction of DNA damage and oxidative stress.

Zeren Shen, Jinjin Shao, Jiabin Dai, Yuchen Lin, Xiaochun Yang, Jian Ma, Qiaojun He, Bo Yang, Ke Yao, Peihua Luo

Open access · goldAbstract read
In one paragraph

Article in Toxicology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Zeren ShenInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, P.R. China.
Jinjin ShaoInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, P.R. China.
Jiabin DaiInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, P.R. China.
Yuchen LinInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, P.R. China.
Xiaochun YangInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, P.R. China.
Jian MaCenter for Drug Safety Evaluation and Research of Zhejiang University, Hangzhou, P.R. China.
Qiaojun HeInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, P.R. China.
Bo YangInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, P.R. China.
Ke YaoEye Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, P.R. China.
Peihua LuoInstitute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, P.R. China.
Zhejiang University · CNSecond Affiliated Hospital of Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Visual impairment is a global public health problem that needs new candidate drugs.

Indexed as

ADR, adriamycinAMD, age-related macular degenerationApoptosisATP, adenosine triphosphateChrysanthemumCNV, choroidal neovascularisationDIO, diosmetinDiosmetinDiosmetin (PubChem CID5281612)DNA damageDoxorubicin (PubChem CID31703)H&E, hematoxylin and eosinIC50, inhibition for 50% of the cellsIVI, intravitreal injectionOxidative stressPVR, proliferative vitreoretinopathyRetinal injuryRetinal pigment epitheliumROS, reactive oxygen speciesRPE, retinal pigment epithelium

Identifiers

PMID28959525
PMCPMC5615423
OpenAlexW2212768539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.